Computer modelling identifies three thymoquinone-like compounds for possible ALS drug development
Original source
Integrated In Silico Discovery of Thymoquinone Analogs Targeting the Keap1-Nrf2 Pathway for Amyotrophic Lateral Sclerosis Therapy. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human
Computer modelling identified three thymoquinone-derived compounds that may bind more strongly than thymoquinone to Keap1, a protein in the Keap1-Nrf2 pathway. The compounds were predicted to have favourable safety properties and to cross the blood-brain barrier. They have not yet been tested in cells, animals or people.
Why this matters
These compounds could be candidates for laboratory testing aimed at developing treatments that influence oxidative-stress pathways in ALS. The findings do not currently change treatment, because the results are based only on computational predictions.
Limitations and context
This was an in silico study using modelling, screening and molecular simulations. The three compounds still need to be tested in vitro and in vivo; the study does not show that they are effective or safe in people with ALS.